mouse anti igf 1r (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
94
Structured Review
Santa Cruz Biotechnology
mouse anti igf 1r
Mouse Anti Igf 1r, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 533 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/igf+ir/IGF-IR+Antibody/pm41934916-54-46-48
Average 94 stars, based on 533 article reviews
Mouse Anti Igf 1r, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 533 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/igf+ir/IGF-IR+Antibody/pm41934916-54-46-48
Average 94 stars, based on 533 article reviews
mouse anti igf 1r - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
Transfection:Article Title: Circulating myomiRNAs as biomarkers in patients with Cushing’s syndrome Article Snippet: .. After 48 h, on day 4, differentiated C2C12, as well as differentiated C2C12 transfected with miRNA inhibitor, were treated with a single dose of HC for 12 h. The cells were incubated with primary antibodies against Atrogin-1 (12,866-AP Proteintech, Chicago USA,) dilution used 1:50; MuRF-1 (E-AB-60840 Elabscience, Houston, Texas,) dilution used 1:1000, and Article Title: Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome. Article Snippet: .. After 48 h, on day 4, differentiated C2C12, as well as differentiated C2C12 transfected with miRNA inhibitor, were treated with a single dose of HC for 12 h. The cells were incubated with primary antibodies against Atrogin-1 (12,866-AP Proteintech, Chicago USA,) dilution used 1:50; MuRF-1 (E-AB-60840 Elabscience, Houston, Texas,) dilution used 1:1000, and Article Title: IPF Pathogenesis is Dependent upon TGFβ Induction of IGF-1 Article Snippet: A summary of pharmacological inhibitors and growth factor treatments found to be optimal in fibroblasts is provided in , unless otherwise noted in a specific method. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Pharmacological Inhibitors Inhibitor Target Catalogue # Source Working Concentration(s) Vehicle SB431542 TGFβ Type 1 Receptor S1067 Selleck Chemicals (Houston, TX, USA) 10 μM 0.1% DMSO LY-294,002 PI3K S1105 Selleck Chemicals (Houston, TX, USA) 20 μM 0.1% DMSO MK2206 AKT S1078 Selleck Chemicals (Houston, TX, USA) 300 nM 0.1% DMSO U0127 MEK V1121 Promega (Madison, WI, USA) 10 μM 0.1% DMSO Rapamycin mTORC1/2 S1039 Selleck Chemicals (Houston, TX, USA) 10 nM 0.1% DMSO OSI-906 IGF-1 Receptor S1091 Selleck Chemicals (Houston, TX, USA) 1 nM, 1 μM, 10 μM 0.1% DMSO Growth Factor Treatments Growth Factor Catalogue # Source Working Concentration(s) Vehicle TGFβ 240-B R&D Systems (Minneapolis, MN, USA) 10 ng/ml 4 mM HCl, 0.1% BSA IGF-1 (mouse) 9897 Cell Signaling (Danvers, MA, USA) 0.2 ng/ml 20mM citrate, pH 3.0 IGF-1 (human) ab9573 Abcam (Cambridge, MA, USA) 2 ng/ml dH 2 O Open in a separate window Summary of cell culture treatments. .. For siRNA knockdown of IGF-1R in AKR-2B murine fibroblasts or MRC5 human lung fibroblasts, cells were transiently transfected with 40 nM of small interfering RNA (siRNA) to Incubation:Article Title: Circulating myomiRNAs as biomarkers in patients with Cushing’s syndrome Article Snippet: .. After 48 h, on day 4, differentiated C2C12, as well as differentiated C2C12 transfected with miRNA inhibitor, were treated with a single dose of HC for 12 h. The cells were incubated with primary antibodies against Atrogin-1 (12,866-AP Proteintech, Chicago USA,) dilution used 1:50; MuRF-1 (E-AB-60840 Elabscience, Houston, Texas,) dilution used 1:1000, and Article Title: Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome. Article Snippet: .. After 48 h, on day 4, differentiated C2C12, as well as differentiated C2C12 transfected with miRNA inhibitor, were treated with a single dose of HC for 12 h. The cells were incubated with primary antibodies against Atrogin-1 (12,866-AP Proteintech, Chicago USA,) dilution used 1:50; MuRF-1 (E-AB-60840 Elabscience, Houston, Texas,) dilution used 1:1000, and Article Title: Improvement of oocyte competence and in vitro oocyte maturation with EGF and IGF-I in Guinea pig model. Article Snippet: Briefly, endogenous peroxidase activity was blocked in deparaffinized sections with normal goat serum (1:10, Santa Cruz Biotechnology). .. Rabbit polyclonal IgG EGF-R and Blocking Assay:Article Title: Circulating myomiRNAs as biomarkers in patients with Cushing’s syndrome Article Snippet: .. After 48 h, on day 4, differentiated C2C12, as well as differentiated C2C12 transfected with miRNA inhibitor, were treated with a single dose of HC for 12 h. The cells were incubated with primary antibodies against Atrogin-1 (12,866-AP Proteintech, Chicago USA,) dilution used 1:50; MuRF-1 (E-AB-60840 Elabscience, Houston, Texas,) dilution used 1:1000, and Article Title: Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome. Article Snippet: .. After 48 h, on day 4, differentiated C2C12, as well as differentiated C2C12 transfected with miRNA inhibitor, were treated with a single dose of HC for 12 h. The cells were incubated with primary antibodies against Atrogin-1 (12,866-AP Proteintech, Chicago USA,) dilution used 1:50; MuRF-1 (E-AB-60840 Elabscience, Houston, Texas,) dilution used 1:1000, and Immunostaining:Article Title: The Effects of Juglone on Cell Proliferation and Insulin-Like Growth Factor I Receptor/Phosphoinositide 3-Kinase/p85 (IGF-IR/PI3K/p85) Signaling Pathway in Pancreatic Cancer Article Snippet: .. Immunostaining was performed using primary antibodies for Staining:Article Title: The Effects of Juglone on Cell Proliferation and Insulin-Like Growth Factor I Receptor/Phosphoinositide 3-Kinase/p85 (IGF-IR/PI3K/p85) Signaling Pathway in Pancreatic Cancer Article Snippet: .. Immunostaining was performed using primary antibodies for Knockdown:Article Title: IPF Pathogenesis is Dependent upon TGFβ Induction of IGF-1 Article Snippet: A summary of pharmacological inhibitors and growth factor treatments found to be optimal in fibroblasts is provided in , unless otherwise noted in a specific method. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Pharmacological Inhibitors Inhibitor Target Catalogue # Source Working Concentration(s) Vehicle SB431542 TGFβ Type 1 Receptor S1067 Selleck Chemicals (Houston, TX, USA) 10 μM 0.1% DMSO LY-294,002 PI3K S1105 Selleck Chemicals (Houston, TX, USA) 20 μM 0.1% DMSO MK2206 AKT S1078 Selleck Chemicals (Houston, TX, USA) 300 nM 0.1% DMSO U0127 MEK V1121 Promega (Madison, WI, USA) 10 μM 0.1% DMSO Rapamycin mTORC1/2 S1039 Selleck Chemicals (Houston, TX, USA) 10 nM 0.1% DMSO OSI-906 IGF-1 Receptor S1091 Selleck Chemicals (Houston, TX, USA) 1 nM, 1 μM, 10 μM 0.1% DMSO Growth Factor Treatments Growth Factor Catalogue # Source Working Concentration(s) Vehicle TGFβ 240-B R&D Systems (Minneapolis, MN, USA) 10 ng/ml 4 mM HCl, 0.1% BSA IGF-1 (mouse) 9897 Cell Signaling (Danvers, MA, USA) 0.2 ng/ml 20mM citrate, pH 3.0 IGF-1 (human) ab9573 Abcam (Cambridge, MA, USA) 2 ng/ml dH 2 O Open in a separate window Summary of cell culture treatments. .. For siRNA knockdown of IGF-1R in AKR-2B murine fibroblasts or MRC5 human lung fibroblasts, cells were transiently transfected with 40 nM of small interfering RNA (siRNA) to Small Interfering RNA:Article Title: IPF Pathogenesis is Dependent upon TGFβ Induction of IGF-1 Article Snippet: A summary of pharmacological inhibitors and growth factor treatments found to be optimal in fibroblasts is provided in , unless otherwise noted in a specific method. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Pharmacological Inhibitors Inhibitor Target Catalogue # Source Working Concentration(s) Vehicle SB431542 TGFβ Type 1 Receptor S1067 Selleck Chemicals (Houston, TX, USA) 10 μM 0.1% DMSO LY-294,002 PI3K S1105 Selleck Chemicals (Houston, TX, USA) 20 μM 0.1% DMSO MK2206 AKT S1078 Selleck Chemicals (Houston, TX, USA) 300 nM 0.1% DMSO U0127 MEK V1121 Promega (Madison, WI, USA) 10 μM 0.1% DMSO Rapamycin mTORC1/2 S1039 Selleck Chemicals (Houston, TX, USA) 10 nM 0.1% DMSO OSI-906 IGF-1 Receptor S1091 Selleck Chemicals (Houston, TX, USA) 1 nM, 1 μM, 10 μM 0.1% DMSO Growth Factor Treatments Growth Factor Catalogue # Source Working Concentration(s) Vehicle TGFβ 240-B R&D Systems (Minneapolis, MN, USA) 10 ng/ml 4 mM HCl, 0.1% BSA IGF-1 (mouse) 9897 Cell Signaling (Danvers, MA, USA) 0.2 ng/ml 20mM citrate, pH 3.0 IGF-1 (human) ab9573 Abcam (Cambridge, MA, USA) 2 ng/ml dH 2 O Open in a separate window Summary of cell culture treatments. .. For siRNA knockdown of IGF-1R in AKR-2B murine fibroblasts or MRC5 human lung fibroblasts, cells were transiently transfected with 40 nM of small interfering RNA (siRNA) to Control:Article Title: IPF Pathogenesis is Dependent upon TGFβ Induction of IGF-1 Article Snippet: A summary of pharmacological inhibitors and growth factor treatments found to be optimal in fibroblasts is provided in , unless otherwise noted in a specific method. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Pharmacological Inhibitors Inhibitor Target Catalogue # Source Working Concentration(s) Vehicle SB431542 TGFβ Type 1 Receptor S1067 Selleck Chemicals (Houston, TX, USA) 10 μM 0.1% DMSO LY-294,002 PI3K S1105 Selleck Chemicals (Houston, TX, USA) 20 μM 0.1% DMSO MK2206 AKT S1078 Selleck Chemicals (Houston, TX, USA) 300 nM 0.1% DMSO U0127 MEK V1121 Promega (Madison, WI, USA) 10 μM 0.1% DMSO Rapamycin mTORC1/2 S1039 Selleck Chemicals (Houston, TX, USA) 10 nM 0.1% DMSO OSI-906 IGF-1 Receptor S1091 Selleck Chemicals (Houston, TX, USA) 1 nM, 1 μM, 10 μM 0.1% DMSO Growth Factor Treatments Growth Factor Catalogue # Source Working Concentration(s) Vehicle TGFβ 240-B R&D Systems (Minneapolis, MN, USA) 10 ng/ml 4 mM HCl, 0.1% BSA IGF-1 (mouse) 9897 Cell Signaling (Danvers, MA, USA) 0.2 ng/ml 20mM citrate, pH 3.0 IGF-1 (human) ab9573 Abcam (Cambridge, MA, USA) 2 ng/ml dH 2 O Open in a separate window Summary of cell culture treatments. .. For siRNA knockdown of IGF-1R in AKR-2B murine fibroblasts or MRC5 human lung fibroblasts, cells were transiently transfected with 40 nM of small interfering RNA (siRNA) to Negative Control:Article Title: Improvement of oocyte competence and in vitro oocyte maturation with EGF and IGF-I in Guinea pig model. Article Snippet: Briefly, endogenous peroxidase activity was blocked in deparaffinized sections with normal goat serum (1:10, Santa Cruz Biotechnology). .. Rabbit polyclonal IgG EGF-R and |
